Janssen Pharmaceuticals wins FDA approval for Erleada(apalutamide) Tablets for the treatment of Prostate Cancer

 FDA approves Erleada Tablets for the treatment of Prostate Cancer

A new drug that can stall the progression of a particularly hard-to-treat form of prostate cancer has been approved for use by U.S. health officials.

Company: Janssen Pharmaceuticals, Inc.

Brand Name: Erleada

Generic Name: apalutamide

Dosage Form: Tablets

Treatment For: Prostate Cancer

 

 

 

General information about Erleada

Erleada (apalutamide) is an oral androgen receptor inhibitor for the treatment of men with non-metastatic castration-resistant prostate cancer (CRPC).

Erleada (apalutamide) has shown breakthrough effectiveness in keeping prostate cancer from spreading for two years in men whose disease had not yet traveled to other parts of their body

 

Our App

Connect with us

Oddway on facebook Oddway on pinterest Oddway on VK Oddway on LinkedIn Oddway on Twitter

Contact Us

  • icon
    Address : 4216/20, Ground Floor, 1 Ansari Road, Daryaganj,
               New Delhi - 110002 (India)
  • icon
    Phone : +91-11-43526658
    Mobile : +91-9873336444
  • icon
    WhatsApp : +91-9873336444
    Viber          : +91-9873336444

Oddway International is a Pharmaceutical Exporter & Supplier of Generic Medicine and Online Pharmacy Distributor in India...Read More

Top